Page last updated: 2024-12-08

sr 12813

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SR 12813: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

SR12813 : An organic phosphonate that is the tetraethyl ester of [2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethene-1,1-diyl]bis(phosphonic acid). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID446313
CHEMBL ID458767
CHEBI ID77317
SCHEMBL ID678403
MeSH IDM0263517

Synonyms (41)

Synonym
BIDD:PXR0009
gtpl2763
sr-12813
sr 12813
gw 485801
126411-39-0
[2-(3,5-di-tert-butyl-4-hydroxy-phenyl)-1-(diethoxy-phosphoryl)-vinyl]-phosphonic acid diethlyl ester
sr12813
NCGC00165888-01
DB04466
1ILH ,
tetra-ethyl-2,(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate
4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol
chebi:77317 ,
CHEMBL458767 ,
S8302
BRD-K67097529-001-01-1
SCHEMBL678403
tetraethyl [2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethene-1,1-diyl]bis(phosphonate)
[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-phosphonic acid tetraethyl ester
AC-32619
AKOS024457360
DTXSID90332221
bdbm50030477
J-005380
sr 12813, >=98%, solid
sr-12813gw 485801
CS-6038
HY-100793
tetraethyl (2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethene-1,1-diyl)bis(phosphonate)
sr-12813;sr12813;gw 485801;gw-485801;gw485801
BCP25726
4-(2,2-bis(diethoxyphosphoryl)ethenyl)-2,6-ditert-butylphenol
phosphonic acid, p,p'-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)ethenylidene)bis-, p,p,p',p'-tetraethyl ester
6q7mn2pvb9 ,
unii-6q7mn2pvb9
Q27088861
CCG-269731
phosphonic acid, p,p'-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-, p,p,p',p'-tetraethyl ester
D84047
BFA41139

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
pregnane X receptor agonistAn agonist that selectively binds to and activates a pregnane X receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
organic phosphonate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency50.11870.354828.065989.1251AID504847
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency12.58930.00798.23321,122.0200AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Orphan Nuclear Receptor PxrHomo sapiens (human)Kd0.04100.04100.04100.0410AID977611
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)0.19330.00203.519610.0000AID1168718; AID1215094; AID1686024
3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)EC50 (µMol)1.10000.47000.76901.1000AID1720618
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (23)

Processvia Protein(s)Taxonomy
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cholesterol biosynthetic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
visual learning3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
coenzyme A metabolic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
negative regulation of protein catabolic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
negative regulation of protein secretion3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
long-term synaptic potentiation3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
regulation of ERK1 and ERK2 cascade3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
negative regulation of amyloid-beta clearance3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
isoprenoid biosynthetic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
sterol biosynthetic process3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
hydroxymethylglutaryl-CoA reductase (NADPH) activity3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
protein binding3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
GTPase regulator activity3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
NADPH binding3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
coenzyme A binding3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
peroxisomal membrane3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
endoplasmic reticulum3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
endoplasmic reticulum membrane3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
endoplasmic reticulum membrane3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
peroxisomal membrane3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID381945Induction of CYP3A4 mRNA expression in human hepatocyte FT269 at 1 uM after 24 hrs by RT-PCR relative to control2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
N-1H-benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists.
AID381948Induction of CYP3B6 mRNA expression in human hepatocyte FT271 at 1 uM after 24 hrs by RT-PCR relative to control2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
N-1H-benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists.
AID1215094Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1686024Agonist activity at human PXR2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
AID381946Induction of CYP3B6 mRNA expression in human hepatocyte FT269 at 1 uM after 24 hrs by RT-PCR relative to control2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
N-1H-benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists.
AID1720620Cytotoxicity against human HEK293 cells assessed as reduction in cell viability at 10 uM incubated for 4 hrs by CytoRed viability assay2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Bisphosphonate esters interact with HMG-CoA reductase membrane domain to induce its degradation.
AID1168718Agonist activity at human pregnane X receptor expressed in HEK293 cells by luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID1720618Induction of degradation of Flag-tagged human HMGCR-dCat-ELuc membrane domain (1 to 499 residues) expressed in HEK293 cells assessed as reduction in HMGCR-dCat-Eluc protein level after 4 hrs by luciferase reporter assay2020Bioorganic & medicinal chemistry, 07-15, Volume: 28, Issue:14
Bisphosphonate esters interact with HMG-CoA reductase membrane domain to induce its degradation.
AID381950Induction of CYP3B6 mRNA expression in human hepatocyte FT272 at 1 uM after 24 hrs by RT-PCR relative to control2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
N-1H-benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists.
AID381949Induction of CYP3A4 mRNA expression in human hepatocyte FT272 at 1 uM after 24 hrs by RT-PCR relative to control2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
N-1H-benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists.
AID381947Induction of CYP3A4 mRNA expression in human hepatocyte FT271 at 1 uM after 24 hrs by RT-PCR relative to control2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
N-1H-benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists.
AID381943Induction of CYP3A4 mRNA expression in human hepatocyte FT268 at 1 uM after 24 hrs by RT-PCR relative to control2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
N-1H-benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists.
AID1899924Binding affinity to human PXR-LBD assessed as change in melting temperature at 100 uM incubated for 30 mins by thermal shift assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Structure-Based and Knowledge-Informed Design of B-Raf Inhibitors Devoid of Deleterious PXR Binding.
AID381944Induction of CYP3B6 mRNA expression in human hepatocyte FT268 at 1 uM after 24 hrs by RT-PCR relative to control2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
N-1H-benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2001Science (New York, N.Y.), Jun-22, Volume: 292, Issue:5525
The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity.
AID1811Experimentally measured binding affinity data derived from PDB2001Science (New York, N.Y.), Jun-22, Volume: 292, Issue:5525
The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity.
AID1346741Human Pregnane X receptor (1I. Vitamin D receptor-like receptors)2000Molecular endocrinology (Baltimore, Md.), Jan, Volume: 14, Issue:1
The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (13.04)18.2507
2000's10 (43.48)29.6817
2010's7 (30.43)24.3611
2020's3 (13.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.33 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index20.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]